Form 4: Shattuck Labs CTO Buys Shares, Warrants in Private Placement

Shattuck Labs' Chief Technical Officer, Abhinav A. Shukla, acquired 5,122 shares and warrants in a private placement, signaling insider confidence.

Summary

• Abhinav A. Shukla, Chief Technical Officer of Shattuck Labs, Inc., acquired 5,122 shares of common stock and accompanying warrants.
• The transaction occurred on August 25, 2025, as part of a private placement, which closed on that date.
• The combined price for each share of common stock and accompanying warrant was $0.8677.
• The warrants allow the purchase of up to 5,122 additional shares of common stock at an exercise price of $1.0846 per share.
• Following this transaction, Mr. Shukla beneficially owns 81,258 shares of common stock and 5,122 warrants.
• The warrants become exercisable upon public announcement of Phase 1 clinical trial data for SL-325, including receptor occupancy and safety data, and the design of planned Phase 2 trials.
• The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 7

Explanation: The insider purchase by a key technical officer, coupled with the acquisition of warrants, suggests strong internal confidence in the company's future, particularly its clinical pipeline. While the warrant exercise is tied to clinical trial success, the investment itself is a positive signal.

Positives

• Insider buying by the Chief Technical Officer suggests confidence in the company's future prospects and valuation.
• The acquisition of warrants indicates a belief in potential future stock price appreciation beyond the exercise price.
• The transaction was part of a private placement, which can be a strategic way for companies to raise capital from informed investors.

Negatives

• The exercise of warrants is contingent on the successful announcement of Phase 1 clinical trial data for SL-325, introducing a dependency on clinical trial outcomes.
• The private placement suggests the company sought capital from accredited investors, which could imply a need for funding.

Risks

• The value and exercisability of the warrants are directly tied to the success and public announcement of data from the Phase 1 clinical trial of SL-325, including receptor occupancy and safety data.
• Failure to achieve positive clinical trial results or delays in data announcement could negatively impact the value of the warrants and the company's stock.
• The company's reliance on clinical trial outcomes for its pipeline assets, such as SL-325, introduces significant development risk inherent in the biotechnology sector.

Future Outlook

The exercisability of the acquired warrants is contingent upon the public announcement of data from the single ascending dose and multiple ascending dose portions of the Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s). This indicates a future milestone tied to clinical development.

Management Comments

• The Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person.
• Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 5,122 shares of the Issuer's common stock and accompanying warrants.

Industry Context

Insider purchases, especially by a Chief Technical Officer in a biotechnology company, can be interpreted as a strong signal of confidence in the company's research pipeline and future prospects. This is particularly relevant in the biotech sector where clinical trial success is a primary value driver. Private placements are common for biotech companies seeking to raise capital for R&D and clinical development.

Comparison to Industry Standards

• Insider buying, particularly by a CTO, is generally viewed positively, aligning with industry observations that management's personal investment often correlates with belief in future success.
• The structure of the private placement, combining shares with warrants, is a common financing mechanism in the biotech industry, often used to attract investors by offering additional upside potential.
• The warrant exercise condition tied to clinical trial milestones (Phase 1 data and Phase 2 design for SL-325) is a standard practice in biotech financing, linking investor returns to scientific progress.

Related Party Transactions

• The Chief Technical Officer, Abhinav A. Shukla, is a related party to Shattuck Labs, Inc.
• The transaction involves the purchase of common stock and warrants directly from the Issuer in a private placement, making it a related party transaction.

Stakeholder Impact

• Shareholders: The insider purchase could be viewed positively, potentially boosting investor confidence. The private placement dilutes existing shareholders to some extent but provides capital for company operations.
• Employees: The company's ability to raise capital through private placements supports ongoing operations and potentially job security.
• Creditors: A successful capital raise strengthens the company's financial position, potentially reducing credit risk.

Next Steps

• Public announcement of data from the single ascending dose and multiple ascending dose portions of the Phase 1 clinical trial of SL-325.
• Public announcement of receptor occupancy and safety data for SL-325.
• Public announcement of the design of planned Phase 2 clinical trial(s) for SL-325.
• Potential exercise of warrants by the Reporting Person following the fulfillment of the exercise conditions.

Key Dates

Recommendation

While insider buying is a positive signal, the company's valuation and future prospects are heavily reliant on the success of its clinical pipeline, particularly the upcoming data for SL-325. The acquisition of warrants by the CTO indicates confidence, but the inherent risks of biotech clinical trials suggest a 'hold' until more definitive clinical data is publicly available. The private placement provides capital but also involves dilution.

Keywords

Shattuck Labs, STTK, Insider Buying, Form 4, Private Placement, Warrants, Biotechnology, Clinical Trials, SL-325, Chief Technical Officer